Intersect ENT, Inc. (XENT)
| Market Cap | 697.18M |
| Revenue (ttm) | 80.55M |
| Net Income (ttm) | -72.32M |
| Shares Out | 32.62M |
| EPS (ttm) | -2.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $18.25 |
| Previous Close | $21.04 |
| Change ($) | -2.79 |
| Change (%) | -13.26% |
| Day's Open | 20.69 |
| Day's Range | 18.25 - 22.08 |
| Day's Volume | 117,873 |
| 52-Week Range | 10.84 - 26.98 |
Intersect ENT (XENT) delivered earnings and revenue surprises of -21.43% and 4.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
PROPEL and SINUVA are expected to have contributed to Intersect ENT's (XENT) first-quarter revenues.
Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 5.56% year over year to ($0.51), which missed the estimate of (...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports First Quarter 2021 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the appoi...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report First Quarter 2021 Financial Results
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Changes to its Board of Directors
Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.
Intersect ENT (XENT) is worried about the first-quarter performance as well on the significant surge in COVID-19 case rates.
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
MENLO PARK, Calif.--(BUSINESS WIRE)--Dr. Neil Hattangadi Joins Intersect ENT's Board of Directors
Intersect ENT's (XENT) sequentially rebound is strong on continued recovery in PROPEL, growth in SINUVA and initial sales of the company???s newly acquired Fiagon products.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference
Intersect ENT (XENT) delivered earnings and revenue surprises of -74.19% and 1.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Fourth Quarter 2020 Financial Results
Intersect ENT (NASDAQ:XENT) releases its next round of earnings this Tuesday, March 09. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the...
Intersect ENT (XENT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S....
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate in Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant
Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intersect ENT's (XENT) potential in chronic sinusitis market and progress in SINUVA and PROPEL product lines are encouraging.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces New Appointments to Executive Leadership Team
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that management will parti...
Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.
Intersect ENT, Inc.'s (XENT) CEO Tom West on Q3 2020 Results - Earnings Call Transcript
Intersect ENT (XENT) delivered earnings and revenue surprises of 22.73% and 0.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Third Quarter 2020 Financial Results
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Third Quarter 2020 Financial Results
MENLO PARK, Calif. & BERLIN--(BUSINESS WIRE)--Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies
MENLO PARK, Calif. and BERLIN--(BUSINESS WIRE)--Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years
Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
Intersect ENT, Inc. (XENT) CEO Thomas West on Q2 2020 Results - Earnings Call Transcript
About XENT
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a steril... [Read more...]
| Industry Medical Devices | IPO Date Jul 24, 2014 |
| CEO Thomas West | Employees 406 |
| Stock Exchange NASDAQ | Ticker Symbol XENT |
Financial Performance
In 2020, Intersect ENT's revenue was $80.55 million, a decrease of -26.19% compared to the previous year's $109.14 million. Losses were -$72.32 million, 68.2% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for Intersect ENT stock is "Buy." The 12-month stock price forecast is 23.71, which is an increase of 29.92% from the latest price.